Spero Therapeutics (SPRO) Equity Average (2017 - 2026)

Spero Therapeutics (SPRO) has 10 years of Equity Average data on file, last reported at $56.0 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 40.05% year-over-year to $56.0 million; the trailing twelve-month figure through Mar 2026 stood at $56.0 million (up 40.05% YoY), and the FY2025 full-year result was $52.6 million, down 31.29% from the prior year.
• Equity Average for Q1 2026 stood at $56.0 million, up from $42.8 million in the prior quarter.
• Across five years, Equity Average topped out at $101.6 million in Q1 2024 and bottomed at $29.7 million in Q3 2025.
• The 5-year median for Equity Average is $55.8 million (2024), against an average of $58.7 million.
• The widest annual swing landed in 2022, when Equity Average sank 66.16%; it then soared 58.59% in 2023.
• A 5-year view of Equity Average shows it stood at $54.2 million in 2022, then surged by 48.13% to $80.3 million in 2023, then plunged by 30.49% to $55.8 million in 2024, then fell by 23.39% to $42.8 million in 2025, then jumped by 30.92% to $56.0 million in 2026.
• The last three Equity Average figures came in at $56.0 million (Q1 2026), $42.8 million (Q4 2025), and $29.7 million (Q3 2025), per Business Quant data.

Peer Comparison